Pleiotropic Effects of GLP-1 Drugs in Heart Failure Patients
Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective, and metabolic mechanisms that benefit HF patients beyond glucose control.
Quick Facts
What This Study Found
Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective, and metabolic mechanisms that benefit HF patients beyond glucose control.
Key Numbers
Review covers GLP-1 RA effects on MASLD/MASH across inflammation, fibrosis, fat metabolism, and microbiome pathways.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The Bigger Picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
What This Study Doesn't Tell Us
Limitations discussed in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to existing evidence?
- ?What research is needed next?
Trust & Context
- Key Stat:
- Key finding Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective
- Evidence Grade:
- Evidence level based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.
- Published In:
- Expert opinion on investigational drugs, 34(3), 169-195 (2025)
- Authors:
- Alkhouri, Naim(4), Charlton, Michael, Gray, Meagan, Noureddin, Mazen
- Database ID:
- RPEP-09871
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean for patients?
Review of GLP-1 drug pleiotropic effects in heart failure covers anti-inflammatory, cardioprotective, and metabolic mechanisms that benefit HF patients beyond glucose control.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09871APA
Alkhouri, Naim; Charlton, Michael; Gray, Meagan; Noureddin, Mazen. (2025). The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.. Expert opinion on investigational drugs, 34(3), 169-195. https://doi.org/10.1080/13543784.2025.2473062
MLA
Alkhouri, Naim, et al. "The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.." Expert opinion on investigational drugs, 2025. https://doi.org/10.1080/13543784.2025.2473062
RethinkPeptides
RethinkPeptides Research Database. "The pleiotropic effects of glucagon-like peptide-1 receptor ..." RPEP-09871. Retrieved from https://rethinkpeptides.com/research/alkhouri-2025-the-pleiotropic-effects-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.